Guangzhou Wondfo Biotech Co.,Ltd (SHE:300482)
China · Delayed Price · Currency is CNY 18.68
+0.23 (1.25%)
Apr 24, 2026, 3:04 PM CST
SHE:300482 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,868 | 2,087 | 3,060 | 2,760 | 5,674 | 3,354 |
Other Revenue | - | - | 5.07 | 5.22 | 6.89 | 7.11 |
| 1,868 | 2,087 | 3,065 | 2,765 | 5,681 | 3,361 | |
Revenue Growth (YoY) | -37.81% | -31.91% | 10.85% | -51.33% | 69.01% | 19.57% |
Cost of Revenue | 844.98 | 897.85 | 1,107 | 1,040 | 2,747 | 1,396 |
Gross Profit | 1,023 | 1,189 | 1,957 | 1,725 | 2,933 | 1,965 |
Selling, General & Admin | 924.71 | 958.29 | 905.85 | 877.11 | 1,157 | 910.24 |
Research & Development | 307.25 | 336.7 | 411.52 | 378 | 418.84 | 391.09 |
Other Operating Expenses | -5.05 | -8.21 | 14.03 | 9.51 | 15.95 | 9.04 |
Operating Expenses | 1,227 | 1,287 | 1,367 | 1,268 | 1,609 | 1,330 |
Operating Income | -203.59 | -97.8 | 590.27 | 456.73 | 1,324 | 634.64 |
Interest Expense | - | - | -30.47 | -29.93 | -32.53 | -27.76 |
Interest & Investment Income | 42.92 | 39.79 | 20.53 | 58.71 | 64.93 | 50.48 |
Currency Exchange Gain (Loss) | - | - | 11.46 | 10.99 | 30.58 | -20.62 |
Other Non Operating Income (Expenses) | -57.94 | -46.93 | -4.16 | -0.59 | -6.59 | -5.67 |
EBT Excluding Unusual Items | -218.61 | -104.94 | 587.63 | 495.91 | 1,381 | 631.08 |
Impairment of Goodwill | - | - | - | -3.95 | -38.56 | -5.87 |
Gain (Loss) on Sale of Investments | 9.36 | 13.64 | 25.75 | 14.8 | 12.81 | 10.55 |
Gain (Loss) on Sale of Assets | 0.32 | 0.32 | 0.76 | 0.08 | -10.4 | -10.34 |
Asset Writedown | -23.61 | -23.71 | -5.96 | -10.77 | -29.96 | - |
Other Unusual Items | - | - | 21.29 | 44.7 | 50.11 | 55.07 |
Pretax Income | -232.53 | -114.69 | 629.46 | 540.76 | 1,365 | 680.49 |
Income Tax Expense | -58.92 | -45.03 | 64.25 | 53.33 | 174.41 | 47.91 |
Earnings From Continuing Operations | -173.61 | -69.66 | 565.22 | 487.43 | 1,190 | 632.58 |
Minority Interest in Earnings | 5.85 | 6.63 | -3.59 | 0.2 | 6.94 | 1.85 |
Net Income | -167.76 | -63.02 | 561.63 | 487.62 | 1,197 | 634.43 |
Net Income to Common | -167.76 | -63.02 | 561.63 | 487.62 | 1,197 | 634.43 |
Net Income Growth | - | - | 15.18% | -59.27% | 88.68% | 0.04% |
Shares Outstanding (Basic) | 481 | 485 | 464 | 443 | 442 | 444 |
Shares Outstanding (Diluted) | 481 | 485 | 464 | 443 | 442 | 444 |
Shares Change (YoY) | 1.43% | 4.45% | 4.71% | 0.36% | -0.44% | 0.74% |
EPS (Basic) | -0.35 | -0.13 | 1.21 | 1.10 | 2.71 | 1.43 |
EPS (Diluted) | -0.35 | -0.13 | 1.21 | 1.10 | 2.71 | 1.43 |
EPS Growth | - | - | 10.00% | -59.41% | 89.51% | -0.69% |
Free Cash Flow | 553.16 | 158.49 | 43.5 | -104.05 | 1,099 | 208.44 |
Free Cash Flow Per Share | 1.15 | 0.33 | 0.09 | -0.23 | 2.49 | 0.47 |
Dividend Per Share | - | - | 0.400 | 0.400 | 0.500 | 0.300 |
Dividend Growth | - | - | - | -20.00% | 66.67% | -22.00% |
Gross Margin | 54.77% | 56.97% | 63.87% | 62.37% | 51.64% | 58.46% |
Operating Margin | -10.90% | -4.69% | 19.26% | 16.52% | 23.31% | 18.88% |
Profit Margin | -8.98% | -3.02% | 18.32% | 17.64% | 21.07% | 18.88% |
Free Cash Flow Margin | 29.61% | 7.60% | 1.42% | -3.76% | 19.35% | 6.20% |
EBITDA | 67.24 | 160.16 | 796.73 | 709.1 | 1,569 | 817.3 |
EBITDA Margin | 3.60% | 7.67% | 26.00% | 25.65% | 27.62% | 24.32% |
D&A For EBITDA | 270.83 | 257.96 | 206.45 | 252.37 | 244.63 | 182.66 |
EBIT | -203.59 | -97.8 | 590.27 | 456.73 | 1,324 | 634.64 |
EBIT Margin | -10.90% | -4.69% | 19.26% | 16.52% | 23.31% | 18.88% |
Effective Tax Rate | - | - | 10.21% | 9.86% | 12.78% | 7.04% |
Revenue as Reported | - | - | 3,065 | 2,765 | 5,681 | 3,361 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.